Patents by Inventor Arthur Pedyczak

Arthur Pedyczak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5
    Patent number: 7342090
    Abstract: The crystal structure of the Fab? fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and complexed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: March 11, 2008
    Assignees: University of Toronto, Sanofi Pasteur Limited
    Inventors: Emil F. Pai, Michel H. Klein, Pele Chong, Arthur Pedyczak
  • MAGE-A1 peptides for treating or preventing cancer
    Publication number: 20030148973
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: May 17, 2002
    Publication date: August 7, 2003
    Inventors: Peter Emtage, Liza Karunakaran, Arthur Pedyczak, Brian H. Barber
  • Fab?-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
    Patent number: 6482928
    Abstract: The crystal structure of the Fab′ fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and completed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: November 19, 2002
    Assignee: Aventis Pasteur Limited and University of Toronto
    Inventors: Emil F. Pai, Michel H. Klein, Pele Chong, Arthur Pedyczak